Appeal 2007-1633
Application 09/480,236
INTRODUCTION
The claims are directed to a recombinant immunotoxin polypeptide or
a pharmaceutically acceptable salt thereof. Claims 35, 50, and 51 are
illustrative:
35. A recombinant immunotoxin polypeptide or a pharmaceutically
acceptable salt thereof comprising a CD3-binding domain and a
Pseudomonas exotoxin (PE) mutant, said PE mutant having ADP-
ribosylating and translocation functions but substantially diminished cell-
binding ability.
50. A recombinant immunotoxin polypeptide or a pharmaceutically
acceptable salt thereof, wherein the polypeptide comprises the polypeptide
encoded by the complement of a nucleotide sequence having at least 300
bases which hybridizes to the nucleotide sequence of claim 49 (SEQ. ID.
NO:2) under stringent hybridization conditions.
51. A recombinant immunotoxin polypeptide or a pharmaceutically
acceptable salt thereof according to claim 36, wherein the CD3-binding
domain comprises the Fv region, or a CD3-binding fragment thereof of an
antibody selected from: monoclonal antibody UCHT-1, an antibody having a
variable region which is at least 90% identical to the variable region of
UCHT-1 as determined by use of the Bestfit program and is at least about
90% as effective on a molar basis in competing with UCHT-1 for binding to
human CD3 antigen and having at least one sequence segment of at least
five amino acids of human origin.
2
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: September 9, 2013